The 5 most recent market catalysts affecting $OLMA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
JP Morgan's analyst Anupam Rama maintained an 'Overweight' rating on Olema Pharmaceuticals, signaling a continued belief in the company's potential for outperformance. However, the…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 55
Olema Oncology Announces Appointment Of Jason O'Byrne As CFO
The appointment of a new CFO, Jason O'Byrne, at Olema Oncology (OLMA) is a standard corporate event. While it doesn't immediately signal a major shift in the company's fundamental …
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 85
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals' announcement of pushing back pivotal Phase 3 OPERA-01 trial data to Q1 2027 is a significant negative catalyst. This delay extends the timeline for potential…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Olema Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results. Also, HC Wainwright & Co. lowered its price target on the stock from $38 to $36.
This headline represents a significant corporate catalyst for Olema Pharmaceuticals. The combination of missing earnings expectations and an analyst downgrade signals fundamental w…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate
Olema Pharmaceuticals (OLMA) announced its Q2 earnings, reporting a loss of $(0.61) per share. This figure not only missed the consensus analyst estimate of $(0.55) by a notable 10…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.